PHILADELPHIA and SAN FRANCISCO, May 18, 2015 /PRNewswire/ -- Velano Vascular shared for the first time today initial work from a research collaboration exploring the impact of the patient and caregiver experience on adoption of new healthcare innovations. Eric M. Stone, Velano Vascular co-founder and CEO, co-presented the project update with Maureen Fagan, DNP, MHA, of Brigham and Women's Hospital, at the Cleveland Clinic 6th Annual Patient Experience: Empathy + Innovation Summit.
Fagan and Stone's poster, Moving the Needle on Patient and Practitioner Wellbeing, shares how the organizations will use a patient-centered methodology to evaluate current inpatient blood-draw practices and identify opportunities for improvement.
"Patients and caregivers have extremely valuable insights and their voices should be included in the healthcare innovation process," said Fagan, who is executive director of The Center for Patient and Family Services and associate chief nurse at Brigham and Women's Hospital (BWH). "Our patients and their families are at the center of all that we do at BWH. Involving them in the evaluation and adoption of new technologies or improvements in care at the outset can lead to improved patient satisfaction and easier pathways to adoption."
Velano Vascular and BWH are using the age-old procedure associated with in-hospital blood draws to build a real-world example of how innovators and clinicians can – and should - integrate the voice of the patient to benefit everyone involved.
Fagan and Stone's presentation highlights the challenges associated with the in-hospital blood draw – one of the most common procedures in medicine - and how the current project will explore improvements to this procedure. In the United States alone, needle sticks (clinically known as venipunctures) for inpatient blood draws occur approximately 350 million times annually. Research conducted by Velano Vascular suggests that one out of every three hospital patients is stuck two or more times daily for blood draws, with a significant subset of these inpatients receiving as many as three blood draws or greater daily, not to mention the additional needle sticks that are often required to gain access to a vein.
In a pivotal study planned for later this year, Velano Vascular and BWH will evaluate a potentially more humane approach to this ubiquitous procedure through the study of Velano Vascular's FDA-cleared blood-draw technology. Additionally, the research team will further evaluate the clinical, patient and family member, and practitioner benefits of this novel approach to inpatient blood draws.
About Velano Vascular
Velano Vascular technologies transform patient care by enhancing the blood-draw experience during hospitalization. The company's innovative medical technologies aim to reduce the pain and discomfort associated with these procedures for patients while improving safety and efficiency for providers. Founded by a patient advocate and a physician, Velano Vascular is backed by First Round Capital, Kapor Capital, Safeguard Scientifics, White Owl Capital, Griffin Hospital, The Children's Hospital of Philadelphia, and several health-industry veterans. Velano Vascular's clinical collaborators include several of the leading hospital systems in the United States. More information is available at www.velanovascular.com
Forward Health Communications, Inc.
SOURCE Velano Vascular